AI-generated summary
The authors compared low-level laser therapy using a red 658 nm laser with standard pharmacotherapy in 180 patients with chronic recurrent aphthous stomatitis, in two groups of 90. They report that the laser group had faster pain relief, faster erythema resolution and more complete epithelization by day 5 than the drug group.
- Participants
- 180
- Who or what was studied
- Patients with chronic recurrent aphthous stomatitis, 90 treated with low-level laser therapy and 90 controls treated with pharmacotherapy
- Wavelengths
- 658 nm
- Limits stated in the abstract
- The abstract does not describe randomization, blinding or long-term follow-up, and the authors' own protocol was developed for this study, so the findings may be less certain than the reported comparisons suggest.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The aim of this study was to clinically assess the therapeutic effect of low-level laser therapy (LLLT) on chronic recurrent aphthous stomatitis (RAS) using a protocol we developed especially for the purpose. The study included 180 patients: group 1 (the study group) - 90 patients who received LLLT using a laser operating in the red spectrum (658 nm; in a non-contact mode; power output P = 27 mW; frequency f1 = 5.8 Hz, f2 - continuous waveform; time T = 1.14 min; dosage of 2 J/cm2 once daily); group 2 (controls) - 90 patients who received pharmacotherapy (Granofurin and solcoseryl given twice daily). The indices we assessed were pain intensity, erythema dynamics and epithelization time. Pain was completely managed in 55.6% of group 1 patients one day after therapy began, while it took three days to alleviate pain for 11.1% of the patients in group 2. The erythema was managed entirely in 24.4% of group 1 patients after the first session, while it did not change in any of the group 2 patients. Pain intensity and erythema had similar dynamics for both groups. In 5 days, 75.6% of group 1 patients showed complete epithelization, while in group 2 the process was completed in only 37.8% of patients. As a whole, the results we obtained using LLLT to treat chronic RAS were better than those obtained in the group receiving pharmacotherapy. Pain and inflammation were very effectively managed with LLLT with the parameters we used and epithelization was considerably accelerated.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 658 nm
- Energy density (fluence)
- 2 J/cm2
- Power
- 27 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Inflammation, Power output. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.